Brokers Issue Forecasts for Sanuwave Health Q2 Earnings

Key Points

• Roth Capital has projected that Sanuwave Health will report a Q2 2025 earnings per share (EPS) of ($0.09) and maintains a "Buy" rating with a target price of $49.00 on the stock.
• Sanuwave Health's recent quarterly earnings showed a loss of ($0.66) EPS with revenue of $9.34 million for the prior quarter.
• Recent insider transactions included significant sales by COO Peter Stegagno and insider Iulian Cioanta, with the latter selling nearly 98.89% of their shares in the company.

Sanuwave Health Inc. (NASDAQ:SNWV - Free Report) - Analysts at Roth Capital issued their Q2 2025 earnings per share (EPS) estimates for Sanuwave Health in a research note issued on Tuesday, July 29th. Roth Capital analyst K. Bauser forecasts that the company will earn ($0.09) per share for the quarter. Roth Capital currently has a "Buy" rating and a $49.00 target price on the stock. Roth Capital also issued estimates for Sanuwave Health's Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.27 EPS, FY2025 earnings at ($0.36) EPS, Q1 2026 earnings at $0.07 EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.36 EPS, FY2026 earnings at $0.84 EPS and FY2027 earnings at $1.72 EPS.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.66) earnings per share for the quarter. The business had revenue of $9.34 million during the quarter.

Separately, Wall Street Zen downgraded Sanuwave Health from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th.

Sanuwave Health Trading Down 5.8%

Shares of NASDAQ:SNWV traded down $2.23 during trading on Thursday, hitting $36.24. 49,625 shares of the company were exchanged, compared to its average volume of 54,710. The firm has a market cap of $310.54 million, a P/E ratio of -7.95 and a beta of 1.24. The firm's 50 day moving average is $32.68. Sanuwave Health has a 52-week low of $5.21 and a 52-week high of $39.83.

Institutional Investors Weigh In On Sanuwave Health

Large investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. purchased a new stake in Sanuwave Health during the first quarter valued at about $337,000. Evernest Financial Advisors LLC purchased a new stake in Sanuwave Health during the second quarter valued at about $823,000. AWM Investment Company Inc. purchased a new stake in Sanuwave Health during the first quarter valued at about $18,153,000. Solas Capital Management LLC purchased a new stake in Sanuwave Health during the first quarter valued at about $20,658,000. Finally, Strategic Investment Solutions Inc. IL purchased a new stake in Sanuwave Health during the first quarter valued at about $47,000. Hedge funds and other institutional investors own 42.53% of the company's stock.

Insiders Place Their Bets

In related news, insider Iulian Cioanta sold 3,639 shares of the stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $31.60, for a total value of $114,992.40. Following the sale, the insider owned 41 shares in the company, valued at approximately $1,295.60. This trade represents a 98.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Peter Stegagno sold 1,862 shares of the stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $27.71, for a total value of $51,596.02. Following the completion of the sale, the chief operating officer owned 2,032 shares in the company, valued at $56,306.72. This trade represents a 47.82% decrease in their position. The disclosure for this sale can be found here. Company insiders own 14.90% of the company's stock.

About Sanuwave Health

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.